Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Core Insights - Kymera Therapeutics, Inc. is set to announce results from the BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader for atopic dermatitis, on December 8, 2025 [1] - KT-621 has shown complete STAT6 degradation and a favorable safety profile in early studies, indicating its potential to transform treatment for over 130 million patients with Type 2 inflammatory diseases [3] - Ongoing and planned clinical trials for KT-621 aim to accelerate its development across multiple indications, including asthma and other Type 2 diseases [4] Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation to develop innovative therapies for significant health issues [5] - The company has advanced the first degrader into clinical evaluation for immunological diseases and aims to build a robust pipeline of oral small molecule degraders [5] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces, reflecting its commitment to innovation and employee satisfaction [5]